セラノスティックスの世界市場

セラノスティックスの世界市場は2030年までに46億米ドルに到達

2024年に20億米ドルと推定されるセラノスティックスの世界市場は、2030年には46億米ドルに達し、分析期間2024-2030年のCAGRは15.2％で成長すると予測されます。セラノスティックス器械は、本レポートで分析したセグメントの1つであり、CAGRは14.8％を記録し、分析期間終了時には27億米ドルに達すると予測されています。セラノスティックス試薬セグメントの成長率は、分析期間でCAGR 16.3％と推定されます。

米国市場は5億4,060万米ドルと推定、中国はCAGR 20.1％で成長予測

米国のセラノスティックス市場は、2024年に5億4,060万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを20.1%として、2030年までに予測市場規模9億9,790万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.2%と13.6%と予測されています。欧州では、ドイツがCAGR約12.1%で成長すると予測されています。

世界のセラノスティックス市場- 主要動向と促進要因のまとめ

セラノスティックスは精密医療の未来か、それとも始まりに過ぎないのか？

画像診断と標的治療の融合であるセラノスティックスは、現代ヘルスケアにおける最も革新的な動向の一つです。このアプローチは、臨床医が単一の分子プラットフォームを用いて病気を検出、監視、治療することを可能にするもので、多くの場合、放射性標識薬剤やコンパニオン診断薬を用いて、個別化された治療戦略を導きます。当初は腫瘍学、特に前立腺、甲状腺、神経内分泌腫瘍に焦点を当てていたが、セラノスティックスは心臓病学、神経学、炎症性疾患などの他の分野にも急速に拡大しています。分子診断学と標的治療デリバリーを結びつけることで、この二重機能モダリティは、慢性疾患や生命を脅かす疾患がどのように特定され、治療されるかを再定義しています。

セラノスティックスの特徴は、患者に特化した治療ができることです。セラノスティックスは、治療効果に関するリアルタイムのフィードバック、疾患の進行の早期発見、治療レジメンの迅速な調整を可能にします。これにより、効果のない治療への曝露を減らし、副作用を最小限に抑えることができます。ヘルスケアが個別化された治療モデルへと移行する中、セラノスティックスは画一的なプロトコルに代わる説得力のある選択肢を提供します。核医学におけるルテチウム-177やガリウム-68のような放射線障害治療薬の採用は、生存率やQOLの改善において有望な結果を示しています。このような開発により、規制当局の承認、放射性医薬品製造への投資、腫瘍医、放射線科医、分子生物学者間の学際的協力も加速しています。

画像技術と放射性医薬品はどのように治療効果を向上させているのか？

セラノスティックスの進化は、核イメージング技術の進歩や新規放射性医薬品の開発と密接に関連しています。PET（陽電子放射断層撮影）やSPECT（単光子放射断層撮影）画像は、分子レベルで疾患バイオマーカーを同定するための礎となっています。悪性細胞に細胞毒性効果を与える標的アイソトープと組み合わせれば、これらの診断ツールは治療ベクターとなります。アクチニウム225やルテチウム177のようなアルファ線やベータ線を放出するアイソトープが利用できるようになったことで、全身毒性を最小限に抑えながら耐性がんを治療する新たな道が開かれました。

さらに、コンパニオン診断薬が標的治療薬と並行して開発され、より精度の高い臨床判断の指針となっています。PSMA（前立腺特異的膜抗原）やソマトスタチン受容体などの分子マーカーは現在、患者の層別化、治療適格性の判定、治療反応のモニタリングに使用されています。サイクロトロンやジェネレーターを用いた放射性同位元素製造の台頭は、特に地域や民間のヘルスケア環境において、これらの薬剤へのアクセスを向上させています。さらに、ナノテクノロジーは、腫瘍ターゲティングの強化、腎毒性の軽減、循環時間の延長を提供する、セラノシス薬剤をカプセル化して送達するために研究されています。これらのブレークスルーは、患者の予後を改善するだけでなく、セラノスティックスを標準化し、より広範な臨床応用を可能にします。

セラノスティックスは、がん治療の経済性と治療成績を再構築できるか？

セラノスティックスは、長期的な治療コストを削減しながら、臨床転帰を改善する強力なツールとして台頭しつつあります。応答者を早期に同定し、高精度で治療を行うことにより、セラノスティックレジメンは、治療サイクルが少なく、副作用が少ないことが多く、その結果、入院期間が短縮され、資源配分が改善されます。プレシジョン・メディシンの取り組みが世界的に広まるにつれ、セラノスティックスはがん治療のアルゴリズムやクリニカルパスに組み込まれつつあります。医療技術評価（HTA）機関や支払者は、特に従来の治療では見返りが少ない転移性がんや末期がんにおいて、その経済的価値を徐々に認めつつあります。

インフラ投資もこの動向に従っています。病院や研究機関は、放射性医薬品の製造能力、サイクロトロンの設置、専門的な画像診断ラボの整備を進め、セラノシス治療に対する需要の高まりに対応しています。核医学専門家、医学物理士、放射性腫瘍専門医の養成プログラムは、特に欧州、北米、アジア太平洋で拡大しています。同時に、バイオテクノロジー企業、放射性医薬品企業、学術センター間の連携により、臨床試験や規制当局への申請が加速しています。このような統合されたエコシステムは、セラノスティックスが最後の砦的な治療やニッチな研究ではなく、がん治療の標準的な要素になるための基礎を築きつつあります。

セラノスティックス市場の急拡大の原動力は？

セラノスティックス市場の成長は、臨床的、技術的、経済的動向に基づくいくつかの相互関連的な要因によって牽引されています。第一に、がんや神経変性疾患の罹患率の増加により、ヘルスケアシステムはより精密で効率的、かつ個別化された治療法の導入を促しています。第二に、放射性医薬品とコンパニオン診断薬の急速な進歩により、オフターゲット効果を低減した二重機能を提供する疾患特異的な治療薬の開発が可能になっています。

第三に、PET/SPECTスキャナーやデジタル画像診断プラットフォームの普及を含む核画像診断インフラの改善により、先進国市場でも新興国市場でも診断誘導治療がより身近なものとなっています。第四に、製薬企業や政府機関による精密医療研究への投資が拡大し、パイプラインの革新と臨床試験の迅速な進行に拍車をかけています。第五に、特にがん領域において、特定の治療薬に有利な薬事規制やファスト・トラック指定がなされることで、市場投入までの時間が短縮され、商業的導入が促進されています。最後に、画像解釈と治療計画におけるAIと機械学習の統合により、診断精度が向上し、治療が最適化されつつあります。これらの要因が相まって、セラノスティックスは患者中心の次世代ヘルスケアにおいて極めて重要な存在となっています。

セグメント

製品（セラノスティックス機器、セラノスティックス試薬、セラノスティックスソフトウェア）、技術（ゲノム技術、プロテオミクス技術、メタボロミクス技術、バイオマーカー技術）、用途（腫瘍学用途、神経学用途、循環器学用途、感染症用途）、最終用途（病院、診断ラボ、研究機関）

調査対象企業の例

• Abbott Laboratories
• Agilent Technologies
• Alpha9 Theranostics
• Bayer AG
• Beckman Coulter（Danaher）
• Cardinal Health
• Curium Pharma
• GE HealthCare
• Illumina Inc.
• Lantheus Holdings
• Molecular Theranostics LLC
• Myriad Genetics
• Novartis AG
• Pfizer Inc.
• Philips HealthCare
• Qiagen N.V.
• Radiopharm Theranostics（RAD）
• RaySearch Laboratories
• Siemens Healthineers
• Telix Pharmaceuticals

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Theranostics Market to Reach US$4.6 Billion by 2030

The global market for Theranostics estimated at US$2.0 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Theranostics Instruments, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Theranostics Reagents segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$540.6 Million While China is Forecast to Grow at 20.1% CAGR

The Theranostics market in the U.S. is estimated at US$540.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$997.9 Million by the year 2030 trailing a CAGR of 20.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.2% and 13.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Theranostics Market - Key Trends & Drivers Summarized

Is Theranostics the Future of Precision Medicine, or Just the Start?

Theranostics, the fusion of diagnostic imaging and targeted therapy, represents one of the most transformative trends in modern healthcare. This approach enables clinicians to detect, monitor, and treat diseases using a single molecular platform, often with radiolabeled agents or companion diagnostics that guide personalized treatment strategies. While initially focused on oncology-particularly for prostate, thyroid, and neuroendocrine tumors-theranostics is rapidly expanding into other areas such as cardiology, neurology, and inflammatory diseases. By linking molecular diagnostics to targeted therapeutic delivery, this dual-function modality is redefining how chronic and life-threatening diseases are identified and treated.

What sets theranostics apart is its capacity for patient-specific treatment. It allows for real-time feedback on therapeutic efficacy, early detection of disease progression, and rapid adjustment of therapeutic regimens. This reduces exposure to ineffective therapies and minimizes side effects. As healthcare moves toward individualized treatment models, theranostics offers a compelling alternative to one-size-fits-all protocols. The adoption of radiotheranostic agents like Lutetium-177 and Gallium-68 in nuclear medicine has shown promising results in improving survival rates and quality of life. These developments are also accelerating regulatory recognition, investment in radiopharmaceutical production, and cross-disciplinary collaboration between oncologists, radiologists, and molecular biologists.

How Are Imaging Technologies and Radiopharmaceuticals Advancing Theranostic Efficacy?

The evolution of theranostics is closely linked to advances in nuclear imaging technologies and the development of novel radiopharmaceutical agents. PET (positron emission tomography) and SPECT (single-photon emission computed tomography) imaging have become cornerstones in identifying disease biomarkers at the molecular level. When paired with targeted isotopes that deliver cytotoxic effects to malignant cells, these diagnostic tools become therapeutic vectors. The increasing availability of alpha and beta-emitting isotopes-such as Actinium-225 and Lutetium-177-has opened new avenues for treating resistant cancers while minimizing systemic toxicity.

In addition, companion diagnostics are being developed alongside targeted therapies to guide clinical decisions with higher precision. Molecular markers such as PSMA (Prostate-Specific Membrane Antigen) and somatostatin receptors are now being used to stratify patients, determine eligibility for therapy, and monitor treatment response. The rise of cyclotron and generator-based radioisotope production is improving access to these agents, particularly in regional and private healthcare settings. Moreover, nanotechnology is being explored to encapsulate and deliver theranostic agents, offering enhanced tumor targeting, reduced renal toxicity, and prolonged circulation times. These breakthroughs are not only improving patient outcomes but also standardizing theranostics for broader clinical application.

Can Theranostics Reshape the Economics and Outcomes of Cancer Care?

Theranostics is emerging as a powerful tool for improving clinical outcomes while reducing long-term treatment costs-an increasingly important consideration in value-based healthcare systems. By identifying responders early and delivering therapy with high precision, theranostic regimens often require fewer treatment cycles and generate fewer side effects, resulting in shorter hospital stays and better resource allocation. As precision medicine initiatives gain traction globally, theranostics is being integrated into oncology treatment algorithms and clinical pathways. Health technology assessment (HTA) bodies and payers are gradually acknowledging its economic value, particularly in metastatic and late-stage cancers where traditional treatments offer diminishing returns.

Infrastructure investments are also following this trend. Hospitals and research institutions are building out radiopharmaceutical manufacturing capabilities, cyclotron installations, and specialized imaging labs to accommodate the rising demand for theranostic services. Training programs for nuclear medicine professionals, medical physicists, and theranostic oncologists are expanding, especially in Europe, North America, and Asia-Pacific. At the same time, collaborations between biotech firms, radiopharmaceutical companies, and academic centers are accelerating clinical trials and regulatory submissions. This integrated ecosystem is laying the groundwork for theranostics to become a standard component of cancer care rather than a last-resort treatment or research niche.

What’s Fueling the Rapid Expansion of the Theranostics Market?

The growth in the theranostics market is driven by several interconnected factors grounded in clinical, technological, and economic trends. First, the increased incidence of cancer and neurodegenerative diseases is prompting healthcare systems to adopt more precise, efficient, and personalized treatment modalities. Second, rapid advancements in radiopharmaceuticals and companion diagnostics are enabling the development of disease-specific theranostic agents that offer dual functionality with reduced off-target effects.

Third, improvements in nuclear imaging infrastructure-including broader deployment of PET/SPECT scanners and digital imaging platforms-are making diagnostic-guided therapy more accessible across both developed and emerging markets. Fourth, growing investments from pharmaceutical companies and government bodies in precision medicine research are fueling pipeline innovation and fast-tracking clinical trials. Fifth, favorable regulatory pathways and fast-track designations for certain theranostic drugs-especially in oncology-are reducing time-to-market and encouraging commercial uptake. Lastly, the integration of AI and machine learning in image interpretation and treatment planning is improving diagnostic accuracy and optimizing therapy delivery. Collectively, these drivers are positioning theranostics as a pivotal force in next-generation, patient-centered healthcare.

SCOPE OF STUDY:

The report analyzes the Theranostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Theranostics Instruments, Theranostics Reagents, Theranostics Software); Technology (Genomics Technology, Proteomics Technology, Metabolomics Technology, Biomarkers Technology); Application (Oncology Application, Neurology Application, Cardiology Application, Infectious Diseases Application); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Agilent Technologies
• Alpha9 Theranostics
• Bayer AG
• Beckman Coulter (Danaher)
• Cardinal Health
• Curium Pharma
• GE HealthCare
• Illumina Inc.
• Lantheus Holdings
• Molecular Theranostics LLC
• Myriad Genetics
• Novartis AG
• Pfizer Inc.
• Philips HealthCare
• Qiagen N.V.
• Radiopharm Theranostics (RAD)
• RaySearch Laboratories
• Siemens Healthineers
• Telix Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Theranostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Adoption of Personalized Medicine Drives Growth in Theranostic Platforms
  • Expansion of Companion Diagnostics in Oncology Enhances Targeted Drug Efficacy
  • Increased Use of Theranostics in Nuclear Medicine Supports Precision Imaging and Therapy
  • Integration of Diagnostic Imaging With Targeted Radiotherapy Boosts Clinical Workflow Efficiency
  • Growth in Radioisotope Development Enhances Dual-Function Diagnostic-Therapeutic Agents
  • Demand for Early Detection and Monitoring of Tumor Response Strengthens Theranostic Relevance
  • Increased Funding for Radiotheranostic Trials Expands Clinical Validation Across Cancer Types
  • Availability of PET/CT and SPECT Technologies Supports Platform Compatibility
  • Advancements in Molecular Imaging Tracers Improve Disease-Specific Targeting
  • Regulatory Fast-Tracking for Breakthrough Theranostic Drugs Encourages Market Entry
  • Adoption in Multi-Modal Oncology Clinics Supports Real-Time Treatment Optimization
  • Expansion of Biomarker-Guided Therapy in Autoimmune and Neurological Disorders Extends Market Potential
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Theranostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Theranostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Theranostics Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Theranostics Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Theranostics Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Theranostics Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Theranostics Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Theranostics Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Cardiology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Cardiology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Infectious Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: World 16-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Genomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: World 16-Year Perspective for Genomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Proteomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: World 16-Year Perspective for Proteomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Metabolomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: World 16-Year Perspective for Metabolomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Biomarkers Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: World 16-Year Perspective for Biomarkers Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 47: USA Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: USA 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: USA 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: USA 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: USA 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Canada 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Canada 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Canada 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Canada 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• JAPAN
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Japan 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Japan 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Japan 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Japan 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• CHINA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 83: China Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: China 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 86: China Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: China 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: China 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: China 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• EUROPE
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Theranostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Europe 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• FRANCE
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 110: France Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: France 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 113: France Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: France 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: France 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: France 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• GERMANY
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: Germany 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: Germany 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: Germany 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: Germany 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Italy 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Italy 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Italy 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Italy 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 146: UK Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: UK 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 149: UK Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: UK 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: UK 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: UK 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Spain 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Spain 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Spain 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Spain 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Russia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Russia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Russia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Russia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Theranostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Australia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Australia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Australia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 220: Australia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• INDIA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 221: India Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 223: India 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 224: India Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 226: India 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 229: India 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 232: India 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 235: South Korea 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 238: South Korea 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 241: South Korea 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 244: South Korea 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Theranostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 259: Latin America 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 262: Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 265: Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 268: Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 271: Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 274: Argentina 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 277: Argentina 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 280: Argentina 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 283: Argentina 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 286: Brazil 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 289: Brazil 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 292: Brazil 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 295: Brazil 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 298: Mexico 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 301: Mexico 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 304: Mexico 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 307: Mexico 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Theranostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 322: Middle East 16-Year Perspective for Theranostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 325: Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 328: Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 331: Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 334: Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 337: Iran 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 340: Iran 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 343: Iran 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 346: Iran 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 349: Israel 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 352: Israel 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 355: Israel 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 358: Israel 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 373: UAE 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 376: UAE 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 379: UAE 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 382: UAE 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030
• AFRICA
  • Theranostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Theranostics by Product - Theranostics Instruments, Theranostics Reagents and Theranostics Software Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 397: Africa 16-Year Perspective for Theranostics by Product - Percentage Breakdown of Value Sales for Theranostics Instruments, Theranostics Reagents and Theranostics Software for the Years 2014, 2025 & 2030
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Theranostics by Application - Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 400: Africa 16-Year Perspective for Theranostics by Application - Percentage Breakdown of Value Sales for Cardiology Application, Infectious Diseases Application, Oncology Application and Neurology Application for the Years 2014, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Theranostics by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 403: Africa 16-Year Perspective for Theranostics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Research Institutes End-Use for the Years 2014, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Theranostics by Technology - Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 406: Africa 16-Year Perspective for Theranostics by Technology - Percentage Breakdown of Value Sales for Genomics Technology, Proteomics Technology, Metabolomics Technology and Biomarkers Technology for the Years 2014, 2025 & 2030

IV. COMPETITION